Ken Griffin Mereo Biopharma Group PLC Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$2.58 - $4.25 $71,724 - $118,150
27,800 Added 38.34%
100,300 $361,000
Q1 2024

May 15, 2024
BUY
$2.3 - $4.05 $131,330 - $231,255
57,100 Added 370.78%
72,500 $239,000
Q4 2023

Feb 14, 2024
BUY
$1.19 - $2.42 $18,326 - $37,268
15,400 New
15,400 $35,000
Q4 2022

Feb 14, 2023
SELL
$0.5 - $1.01 $9,100 - $18,382
-18,200 Reduced 17.07%
88,400 $66,000
Q3 2022

Nov 14, 2022
BUY
$0.82 - $1.73 $8,774 - $18,511
10,700 Added 11.16%
106,600 $92,000

Others Institutions Holding MREO

# of Institutions
85
Shares Held
102M
Call Options Held
121K
Put Options Held
208K
View Full List

About Mereo Biopharma Group plc

MREO Quotes by TradingView
  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $531M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email